Drug
Ndi 034858 Study Drug
Ndi 034858 Study Drug: highest development phase Phase 2, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| NDI-034858 study drug NCT04999839 | Phase 2 | Moderate to Severe Plaque Psoriasis |
Latest
No recent events.
Follow Ndi 034858 Study Drug on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.